Studying the Effects of Sibutramine on Eating Behavior

• Status: Terminated
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating behavior, cognitive functioning, and psychological functioning under sibutramine and placebo conditions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: AstraZeneca
• Treatments: Sibutramine

Criteria

Inclusion Criteria:

• moderately obese

• stable weight for a minimum of 3 months

• systolic blood pressure less than or equal to 140 mm Hg

• diastolic blood pressure less than or equal to 90 mm Hg

• pulse less than or equal to 95 beats per minute

• English language proficiency

Exclusion Criteria:

• on medications known to affect appetite, weight, or metabolism

• current or past history of: binge eating disorder, anorexia nervosa or bulimia nervosa, major depression

• current or past evidence of psychosis, bipolar illness

• current or past history of alcohol or drug abuse or dependence

• known history of learning disorder or developmental disability

• current or past attention deficit hyperactivity disorders

• low platelet count

• current diabetes mellitus

• uncontrolled asthma, or controlled only with oral steroids

• hypothyroidism not adequately treated

• pregnancy, planning to become pregnant, or lactation within the previous 6 months

• history of neurological disorder or injury

• history of moderate or severe head injury

• waist circumference greater than 188 cm

• indwelling metallic object, non-removable metal jewelery, medicinal patch or recent metallic ink tattoo

• pacemaker

• metallic implants

• medication patches

• significant claustrophobia

• color blindness